Search Results

INOVIO announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

INOVIO today announced that INOVIO’s President and CEO, Dr. Jacqueline Shea , and Chief Medical Officer, Dr. Michael Sumner will participate in a virtual fireside chat hosted by Sudan Loganathan, Ph.D., Managing Director and equity research analyst at Stephens, Inc.

INOVIO today announced that management will participate in the following investor conferences during the month of May.

INOVIO announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.

INOVIO today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024.

INOVIO today announced that it has made equity grants to two newly hired employees under its 2022 Inducement Plan (the “Inducement Plan”).

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments.

INOVIO announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.

INOVIO Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case before underwriting discounts and commissions.